I would tend to agree NZT. My understanding is that MPL had been approved for testing cancer patients in Phase 2 trials but this had been put on hold due to the palatability of the liquid MPL version. The point being if it was okay to use it for phase 2 trials on cancer patients then surely it would be okay for similar trials on a Covid-19 patient? Or am I missing something?
Covi-Pantel . NZ Trader Release, page-14
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.3¢ | $108.2K | 647.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 109170 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 117939 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |